Tags

Type your tag names separated by a space and hit enter

Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma.

Abstract

BACKGROUND

The Physicians' Health Study was a randomized, double-blind, placebo-controlled trial using a 2x2 factorial design including supplementation with beta-carotene (50 mg every other day) in the primary prevention of cancer among 22,071 U.S. male physicians ages 40-84 years at randomization. Before randomization, the authors collected baseline blood specimens to determine whether any benefit was greater among or confined to those with low baseline levels of beta-carotene.

METHODS

Baseline blood samples were collected from 14,916 participants. These samples were assayed, according to a nested case-control design, from 1439 men subsequently diagnosed with cancer over 12 years of follow-up (631 with prostate carcinoma) and 2204 controls matched by age and smoking habits.

RESULTS

Men in the lowest quartile for plasma beta-carotene at baseline had a marginally significant (P = 0.07) increased risk of cancer compared with those in the highest quartile (relative risk [RR] = 1.30, 95% confidence interval [CI], 0.98-1.74). Men in the lowest quartile assigned at random to beta-carotene supplementation had a possible but nonsignificant decrease in overall cancer risk (RR = 0.83, 95% CI, 0.63-1.09) compared with those assigned to placebo. This was primarily due to a significant reduction in the risk of prostate carcinoma (RR = 0.68, 95% CI, 0. 46-0.99) in this group. After the first 2 years of follow-up were excluded, the results were virtually unchanged.

CONCLUSIONS

These prespecified subgroup analyses appeared to support the idea that beta-carotene supplementation may reduce risk of prostate carcinoma among those with low baseline levels. Further follow-up of this population will help determine whether these findings are valid.

Authors+Show Affiliations

,

Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA.

, , , , ,

Source

Cancer 86:9 1999 Nov 01 pg 1783-92

MeSH

Adult
Aged
Aged, 80 and over
Case-Control Studies
Colonic Neoplasms
Dietary Supplements
Double-Blind Method
Epidemiologic Studies
Follow-Up Studies
Humans
Lung Neoplasms
Lymphoma
Male
Melanoma
Middle Aged
Prostatic Neoplasms
Risk
Smoking
beta Carotene

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

10547552

Citation

Cook, N R., et al. "Beta-carotene Supplementation for Patients With Low Baseline Levels and Decreased Risks of Total and Prostate Carcinoma." Cancer, vol. 86, no. 9, 1999, pp. 1783-92.
Cook NR, Stampfer MJ, Ma J, et al. Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer. 1999;86(9):1783-92.
Cook, N. R., Stampfer, M. J., Ma, J., Manson, J. E., Sacks, F. M., Buring, J. E., & Hennekens, C. H. (1999). Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer, 86(9), pp. 1783-92.
Cook NR, et al. Beta-carotene Supplementation for Patients With Low Baseline Levels and Decreased Risks of Total and Prostate Carcinoma. Cancer. 1999 Nov 1;86(9):1783-92. PubMed PMID: 10547552.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. AU - Cook,N R, AU - Stampfer,M J, AU - Ma,J, AU - Manson,J E, AU - Sacks,F M, AU - Buring,J E, AU - Hennekens,C H, PY - 1999/11/5/pubmed PY - 1999/11/5/medline PY - 1999/11/5/entrez SP - 1783 EP - 92 JF - Cancer JO - Cancer VL - 86 IS - 9 N2 - BACKGROUND: The Physicians' Health Study was a randomized, double-blind, placebo-controlled trial using a 2x2 factorial design including supplementation with beta-carotene (50 mg every other day) in the primary prevention of cancer among 22,071 U.S. male physicians ages 40-84 years at randomization. Before randomization, the authors collected baseline blood specimens to determine whether any benefit was greater among or confined to those with low baseline levels of beta-carotene. METHODS: Baseline blood samples were collected from 14,916 participants. These samples were assayed, according to a nested case-control design, from 1439 men subsequently diagnosed with cancer over 12 years of follow-up (631 with prostate carcinoma) and 2204 controls matched by age and smoking habits. RESULTS: Men in the lowest quartile for plasma beta-carotene at baseline had a marginally significant (P = 0.07) increased risk of cancer compared with those in the highest quartile (relative risk [RR] = 1.30, 95% confidence interval [CI], 0.98-1.74). Men in the lowest quartile assigned at random to beta-carotene supplementation had a possible but nonsignificant decrease in overall cancer risk (RR = 0.83, 95% CI, 0.63-1.09) compared with those assigned to placebo. This was primarily due to a significant reduction in the risk of prostate carcinoma (RR = 0.68, 95% CI, 0. 46-0.99) in this group. After the first 2 years of follow-up were excluded, the results were virtually unchanged. CONCLUSIONS: These prespecified subgroup analyses appeared to support the idea that beta-carotene supplementation may reduce risk of prostate carcinoma among those with low baseline levels. Further follow-up of this population will help determine whether these findings are valid. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/10547552/Beta_carotene_supplementation_for_patients_with_low_baseline_levels_and_decreased_risks_of_total_and_prostate_carcinoma_ L2 - https://medlineplus.gov/prostatecancer.html DB - PRIME DP - Unbound Medicine ER -